MMRF PRESS RELEASES
The Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) Appoint Michael N. Needle, M.D., Chief Medical Officer
Norwalk, CT — April 9, 2012
The Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) today announced that Michael N. Needle, M.D., will serve as Chief Medical Officer of both organizations. Dr. Needle will be a member of the MMRF and MMRC Executive Committee and will report directly to Kathy Giusti, MMRF and MMRC Founder and Chief Executive Officer.
Dr. Needle brings more than 25 years of experience as a practicing physician and pharmaceutical executive working in drug development and regulatory affairs to the MMRF and MMRC. On a day to day basis, he will oversee the majority of the MMRC clinical development operations and serve as co-principal investigator of the landmark MMRF CoMMpassSM (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) study.
"Dr. Needle brings more than two decades of exceptional experience from the pharmaceutical industry and academia to the MMRF and MMRC,” said Giusti. “With his background, I have no doubt that he will play a vital role in shaping the organizations’ clinical strategy and ensuring that we deliver on our mission, working in close collaboration with our partners.”
Prior to joining the MMRF and MMRC, Dr. Needle served as Vice President of Clinical Research and Development in Oncology, Strategic Medical Business Development and Pediatric Strategy at Celgene Corporation. Before his tenure at Celgene, Dr. Needle served as the Medical Affairs Officer and Vice President of Clinical Affairs at Imclone Systems Incorporated. Most recently, Dr. Needle served as Assistant Professor of Clinical Pediatrics and Medical Director for the Hematology/Oncology/Stem Cell transplant inpatient unit at the Morgan Stanley Children’s Hospital, where he will continue to maintain a clinical practice.
“With the tools available to us now and new tools emerging in the future, I envision the MMRF continuing to play a role in furthering our understanding of what drives multiple myeloma and use that knowledge to advance patient care,” said Needle. “At the same time, we will stop at nothing to improve the care of patients with multiple myeloma and continue to set the example of a productive patient-focused partnership between a foundation, academic centers, community physicians, and the pharmaceutical and biotech industries.”
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2012, more than 21,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $190 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated more than 35 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donors' investments, the MMRF has been consistently recognized for its sound fiscal management. For more information about the MMRF, please visit www.themmrf.org.
About the Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions. Barbara Anne Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University in St Louis. The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas in genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.
# # #
Anne Quinn Young, MPH, MMRF/MMRC